



CIN No. L24232PB1983PLC005426

GST No. 03AAACK6458M1ZB

D.L. No. 1800-OSP, 1804-B

I.E. Code No. 1293001210

**KWALITY PHARMACEUTICALS LIMITED**

Regd. Office: Village Nag Kalan, Majitha Road, Amritsar - 143 601 (INDIA)

Phone : 91-8558820862 (Accounts)  
: 91-8558820863 (Admin.)  
: 91-9915743720 (Exports)  
M.D. Mobile : 91-9814071215, 9814052314  
E-mail : export@kwalitypharma.com  
ramesh@kwalitypharma.com

Date: February 06, 2024

To  
The Department of Corporate Services  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street,  
Mumbai-400001

**Subject: Outcome of Board Meeting Held on 06<sup>th</sup> February, 2024 and Submission of Unaudited Financial Results for the quarter and nine months ended 31<sup>st</sup> December, 2023**

**Ref: Scrip Code: 539997**

Dear Sir/Madam,

Pursuant to Regulation 30 & 33 read with clause 4 (h) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulation, 2015 ("Listing Regulations"), this is to inform your that Board of Directors in its meeting held today i.e., February 06, 2024, have inter-alia , considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended 31<sup>st</sup> December, 2023 along with Limited Review Report issued by Statutory Auditors of the Company. A copy of the same is enclosed herewith.

The Board Meeting of the Company commenced at 5:00 P.M. and concluded at 7:20 P.M.

Kindly take the above on your record.

For **Kwality Pharmaceuticals Limited**

**Ramesh Arora**  
Managing Director  
DIN:00462656





**KWALITY PHARMACEUTICALS LIMITED**

Regd. Office.:- VILLAGE NAGKALAN, MAJITHA ROAD, AMRITSAR – 143601

CIN.:- L24232PB1983PLC005426; Phone no. :- 8558820863

Email Id:-[ramesh@kwalitypharma.com](mailto:ramesh@kwalitypharma.com); Website :- [www.kwalitypharma.com](http://www.kwalitypharma.com)

---

---

**Management Discussion and Analysis**

Kwality Pharma's consolidated revenue increased by 38.95% YoY and 12.13% QoQ to Rs 78.1 cr in Q3FY24. This growth was driven by expansion into new geographies & new product approvals from various markets.

During the quarter, EBITDA stood at Rs 17.3 cr, sequentially up by 11.6% with slight improvement in EBITDA margins at 22.16%. Net profit stood at Rs 7.67 cr sequentially up 24%.

Management is of the view that company is at the verge of reporting improved performance from here onwards on the back of new product approval and ramp up in supply of existing approved products across semi regulated & regulated markets. Investment made in the past in upgradation of facilities, new capex, in research and development and dossier filings across various semi regulated and regulated markets are likely to pay the fruits in upcoming period. As stated earlier, company is very much on track to double its revenue by FY26 compared to FY23 sales of around Rs 251 cr with sustainable EBITDA margins range of 22-25%.

In addition, this year Kwality received three registrations in semi-regulated and twenty-five new registrations in unregulated markets, which will help boost company's profitability going forward. Kwality has capabilities to manufacture complex long acting injectables, Liposomal, Lyophilized and protein based injectables. It continues to invest in research and development to develop healthy pipeline of complex molecules which are going off-patent in coming years.

*Ramesh*





**GAURAV AGGARWAL**  
Chartered Accountant  
B.Com, FCA, DISA(ICAI)

# 1, Second Floor, J.K. Towers, Mall Road, Amritsar.  
Tel.: **0183 5030348** Mobile : **+91 98143 10561**  
E-mail: gauravca77@yahoo.com  
Website : www.aroraaggarwal.com

**INDEPENDENT AUDITOR'S REVIEW REPORT ON STANDALONE UNAUDITED FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER ENDED 31<sup>ST</sup> DECEMBER, 2023 AND YEAR TO DATE FROM 01<sup>ST</sup> APRIL, 2023 TO 31<sup>ST</sup> DECEMBER, 2023 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)**

To,

**The Board of Directors of  
Kwality Pharmaceuticals Limited.**

1. We have reviewed the accompanying statement of standalone unaudited financial results of **Kwality Pharmaceuticals Limited** ("the company) for the quarter ended on **31<sup>st</sup> December, 2023** and year to date from **01<sup>st</sup> April, 2023 to 31<sup>st</sup> December, 2023** ("the statement) being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)
2. This statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with the Regulations 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.





# ARORA AGGARWAL & CO.

Chartered Accountants

## GAURAV AGGARWAL

Chartered Accountant  
B.Com, FCA, DISA(ICAI)

# 1, Second Floor, J.K. Towers, Mall Road, Amritsar.

Tel.: 0183 5030348 Mobile : +91 98143 10561

E-mail: gauravca77@yahoo.com

Website : www.aroraaggarwal.com

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with applicable Indian Accounting Standards ("Ind AS") and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For ARORA AGGARWAL & CO.  
Chartered Accountants


  
CA GAURAV AGGARWAL

Partner

M. No: 098347

FRN: 021086N

UDIN:-24098347BKFMZV6331



Place: Amritsar

Date: 06-02-2024

**GAURAV AGGARWAL**Chartered Accountant  
B.Com, FCA, DISA(ICAI)

# 1, Second Floor, J.K. Towers, Mall Road, Amritsar.

Tel.: 0183 5030348 Mobile : +91 98143 10561

E-mail: gauravca77@yahoo.com

Website : www.aroraaggarwal.com

**INDEPENDENT AUDITOR'S REVIEW REPORT ON CONSOLIDATED UNAUDITED FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER ENDED 31<sup>ST</sup> DECEMBER, 2023 AND YEAR TO DATE FROM 01<sup>ST</sup> APRIL, 2023 TO 31<sup>ST</sup> DECEMBER, 2023 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)**

To,

**The Board of Directors of  
Kwality Pharmaceuticals Limited.**

1. We have reviewed the accompanying statement of consolidated unaudited financial results of **Kwality Pharmaceuticals Limited ("the Parent")** and its subsidiary (the Parent and its subsidiary together referred to as "the Group"), and its share of the net profit/(loss) after tax for the quarter ended 31<sup>st</sup> December, 2023 and year to date from 01<sup>st</sup> April, 2023 to 31<sup>st</sup> December, 2023 being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with the Regulations 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.





# ARORA AGGARWAL & CO.

Chartered Accountants

## GAURAV AGGARWAL

Chartered Accountant  
B.Com, FCA, DISA(ICAI)

# 1, Second Floor, J.K. Towers, Mall Road, Amritsar.

Tel.: 0183 5030348 Mobile : +91 98143 10561

E-mail: gauravca77@yahoo.com


Website : www.aroraaggarwal.com

4. The Statement includes the results of the following entities:

**Kwality Pharmaceuticals Africa Limitada (Foreign subsidiary)**

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement of consolidated unaudited financial results prepared in accordance with applicable Indian Accounting Standards ("Ind AS") and other accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The consolidated unaudited financial results includes the interim financial statements/ financial information/ financial results of subsidiary which have not been reviewed/audited by us, whose interim financial statements/ financial information/ financial results reflect total revenue of Rs. 0.00 **Lacs** for the quarter ended 31<sup>st</sup> December, 2023, total Profit /(loss) after tax of Rs. **-2.53 Lacs** and total comprehensive income / loss of Rs. **-0.50 Lacs** for the quarter 31<sup>st</sup> December, 2023 as considered in consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements / financial information / financial results are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

For ARORA AGGARWAL & CO.  
Chartered Accountants



CA GAURAV AGGARWAL  
Partner  
M. No: 098347  
FRN: 021086N  
UDIN:- 24098347BKFMZW2686

Place: Amritsar  
Date: 06-02-2024

## KWALITY PHARMACEUTICALS LIMITED

Regd. Office:- VILLAGE NAGKALAN, MAJITHA ROAD, AMRITSAR –

CIN :- L24232PB1983PLC005426; Phone no. :- 8558820862

Email Id:- ramesh@kwalitypharma.com; Website :- www.kwalitypharma.com

### Unaudited Standalone Statement of Financial Results for the Quarter and Nine Months Ended December 31, 2023

(Rs. in lakhs)

Sr.No.	PARTICULARS	Quarter ended			Nine months period ended		Year ended
		December 31, 2023 (Unaudited)	September 30, 2023 (Unaudited)	December 31, 2022 (Unaudited)	December 31, 2023 (Unaudited)	December 31, 2022 (Unaudited)	March 31, 2023 (Audited)
I.	Revenue from operations	7809.50	6964.95	5600.97	21519.45	18219.11	25099.47
II.	Other income	61.77	23.36	35.18	124.75	148.09	294.12
III.	<b>Total Revenue(I+II)</b>	<b>7871.27</b>	<b>6988.30</b>	<b>5636.15</b>	<b>21644.20</b>	<b>18367.21</b>	<b>25393.60</b>
IV.	<b>Expenses</b>						
	(a) Cost of materials consumed	3954.02	3305.91	2388.92	10608.24	8264.77	11322.40
	(b) Purchases of stock-in-trade	62.64	12.50	0.00	85.34	02.66	4.25
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-21.73	96.49	-330.18	21.72	-728.02	-319.94
	(d) Employee benefits expense	800.43	791.64	803.16	2354.15	2202.56	2989.75
	(e) Finance Cost	273.32	241.14	194.97	733.01	435.22	602.04
	(f) Depreciation and amortisation expense	481.15	487.69	354.42	1446.77	1050.23	1491.88
	(g) Other expenses	1343.90	1231.93	1221.80	3872.53	3600.16	5074.14
	<b>Total expenses(IV)</b>	<b>6893.73</b>	<b>6167.29</b>	<b>4633.09</b>	<b>19121.76</b>	<b>14827.58</b>	<b>21164.53</b>
V.	Profit/(Loss) from operations before Exceptional items and Tax (III-IV)	<b>977.55</b>	<b>821.02</b>	<b>1003.06</b>	<b>2522.44</b>	<b>3539.63</b>	<b>4229.07</b>
VI.	Exceptional items	.00	0.00	0.00	0.00	0.00	1652.94
VII.	Profit / (Loss) before Tax (V-VI)	<b>977.55</b>	<b>821.02</b>	<b>1003.06</b>	<b>2522.44</b>	<b>3539.63</b>	<b>2576.13</b>
VIII.	Tax expense:						
	(1) Current tax	246.03	206.63	252.47	634.85	890.85	648.36
	(2) Deferred tax	-38.78	-19.59	27.88	-61.22	-03.01	13.66
	(3) Income tax relating to earlier years	0.00	8.26	0.00	8.26	-30.67	-32.77
	(4) MAT Credit (Entitlement)/Utilised	0.00	.00	0.00	0.00	0.00	.00
IX.	Profit/(Loss) after Tax (VII-VIII)	<b>770.29</b>	<b>625.71</b>	<b>722.71</b>	<b>1940.55</b>	<b>2682.46</b>	<b>1946.88</b>
X.	Other Comprehensive Income(net of tax)						
	(i) Items that will not be reclassified to profit or loss	-.46	-.10	-04.71	-8.86	-25.91	-32.57
	(ii) Items that will be reclassified to profit or loss	.00	.00	.00	.00	.00	.00
	<b>Total Other Comprehensive Income(net of tax)</b>	<b>-.46</b>	<b>-.10</b>	<b>-4.71</b>	<b>-8.86</b>	<b>-25.91</b>	<b>-32.57</b>

*Ramesh Kumar*



	Total Other Comprehensive Income for the period (IX+X)(Comprehensive Profit/(Loss) and Other Comprehensive Income for the period						
XI.		769.83	625.61	718.00	1931.69	2656.55	1914.31
XII.	Paid up Equity Share Capital (Face value Rs.10 each)	1037.62	1037.62	1037.62	1037.62	1037.62	1037.62
XIII.	Other Equity(excluding revaluation reserve)	.00	.00	.00	.00	.00	19084.90
XIV.	Earnings per equity share (Non annualised) (In Rs.)						
	(1) Basic	7.42	6.03	06.92	18.62	25.60	18.45
	(2) Diluted	7.42	6.03	06.92	18.62	25.60	18.45

FOR KWALITY PHARMACEUTICALS LIMITED

Date:- 06.02.2024  
Place:- Amritsar

*Ramesh Arora*

RAMESH ARORA  
Managing Director  
DIN: 00462656





**KWALITY PHARMACEUTICALS LIMITED**

Regd. Office :- VILLAGE NAGKALAN, MAJITHA ROAD, AMRITSAR – 143601

CIN :- L24232PB1983PLC005426; Phone no. :- 8558820862

Email Id:- ramesh@kwalitypharma.com; Website :- www.kwalitypharma.com

**Unaudited Consolidated Statement of Financial Results for the Quarter and Nine Months Ended December 31, 2023**

(Rs. in lakhs)


Sr.No.	PARTICULARS	Quarter ended			Nine months ended		Year ended
		31st DECEMBER 2023 (Unaudited)	30th September 2023 (Unaudited)	31st DECEMBER 2022 (Unaudited)	31st December 2023 (Unaudited)	31st December 2022 (Unaudited)	31st March 2023 (Audited)
I.	Revenue from operations	7809.50	6964.95	5620.25	21519.45	18222.64	25103.00
II.	Other income	61.77	23.36	35.18	124.75	148.09	294.12
III.	<b>Total Revenue(I+II)</b>	<b>7871.27</b>	<b>6988.30</b>	<b>5655.43</b>	<b>21644.20</b>	<b>18370.74</b>	<b>25397.13</b>
IV.	Expenses						
	(a) Cost of materials consumed	3954.02	3305.91	2388.92	10608.24	8264.77	11322.40
	(b) Purchases of stock-in-trade	62.64	12.50	.00	85.34	2.66	4.25
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-21.73	96.49	-314.42	21.72	-728.02	-319.94
	(d) Employee benefits expense	800.87	792.45	804.81	2356.38	2207.54	2995.93
	(e) Finance Cost	273.32	241.14	194.97	733.01	435.22	602.04
	(f) Depreciation and amortisation expense	481.95	488.49	355.41	1449.18	1053.20	1495.84
	(g) Other expenses	1345.18	1234.49	1231.07	3878.94	3610.16	5086.42
	<b>Total expenses(IV)</b>	<b>6896.25</b>	<b>6171.46</b>	<b>4660.76</b>	<b>19132.80</b>	<b>14845.53</b>	<b>21186.95</b>
V.	Profit before share of profit of equity accounted investees, exceptional items and tax (III-IV)	<b>975.02</b>	<b>816.85</b>	<b>994.67</b>	<b>2511.40</b>	<b>3525.20</b>	<b>4210.18</b>
VI.	Share of profit/(loss) of equity accounted investees (net of income tax)	.00	.00	.00	.00	.00	.00
VII.	Profit before exceptional items and tax (VI+VII)	<b>975.02</b>	<b>816.85</b>	<b>994.67</b>	<b>2511.40</b>	<b>3525.20</b>	<b>4210.18</b>
VIII.	Exceptional items	.00	.00	.00	.00	.00	1652.94
IX.	Profit / (Loss) before Tax (VII-VIII)	<b>975.02</b>	<b>816.85</b>	<b>994.67</b>	<b>2511.40</b>	<b>3525.20</b>	<b>2557.24</b>
X.	Tax expense:						
	(1) Current tax	246.03	206.63	252.47	634.85	890.85	648.36
	(2) Deferred tax	-38.78	-19.59	27.88	-61.22	-3.01	13.66
	(3) Income tax relating to earlier years	.00	8.26	.00	8.26	-30.67	-32.77
	(4) MAT Credit (Entitlement)/Utilised	.00	.00	.00	.00	.00	.00
XI.	Profit/(Loss) after Tax (VII-VIII)	<b>767.76</b>	<b>621.54</b>	<b>714.32</b>	<b>1929.51</b>	<b>2668.03</b>	<b>1927.99</b>
XII.	Other Comprehensive Income						
	(i) Items that will not be reclassified subsequently to profit or loss						
	<b>a) Remeasurement of defined benefit plans(net Tax)</b>	<b>-46</b>	<b>-10</b>	<b>-4.71</b>	<b>-8.86</b>	<b>-25.91</b>	<b>-32.57</b>
	(ii) Items that will be reclassified subsequently to profit or loss	.00	.00	.00	.00	.00	.00
	Exchange differences in translating financial statements of foreign operations	-50	-1.05	-2.00	-4.06	-8.21	-11.36
	<b>Total Other Comprehensive Income(net of tax)</b>	<b>-96</b>	<b>-1.15</b>	<b>-6.71</b>	<b>-12.92</b>	<b>-34.12</b>	<b>-43.93</b>
	<b>Total comprehensive income for the period(XI+XII)</b>	<b>766.81</b>	<b>620.39</b>	<b>707.61</b>	<b>1916.59</b>	<b>2633.91</b>	<b>1884.06</b>

*Ramesh*


XIII.	Profit/(loss) attributable to:						
	a) Owners of the Company	769.00	623.58	709.98	1934.92	2675.10	1937.24
	b) Non-controlling interests	-1.24	-2.04	-4.38	-5.41	-7.07	-9.26
XIV.	Other comprehensive income attributable to:						
	a) Owners of the Company	-96	-1.15	-6.71	-12.92	-34.12	-43.93
	b) Non-controlling interests	.00	.00	.00	.00	.00	.00
XV.	Total other comprehensive income attributable to:						
	a) Owners of the Company	768.05	622.43	703.27	1922.00	2640.98	1893.32
	b) Non-controlling interests	-1.24	-2.04	-4.38	-5.41	-7.07	-9.26
XVI.	Paid up Equity Share Capital (Face value Rs.10 each)	1037.62	1037.62	1037.62	1037.62	1037.62	1037.62
XVII.	Reserves i.e. Other equity	.00	.00	.00	.00	.00	18934.03
XVIII.	Earnings per equity share (Non annualised) (In Rs.)						
	(1) Basic	7.39	5.99	6.82	18.47	25.38	18.16
	(2) Diluted	7.39	5.99	6.82	18.47	25.38	18.16

Date:- 06.02.2024  
Place:- Amritsar

FOR KWALITY PHARMACEUTICALS LIMITED



**RAMESH ARORA**  
Managing Director  
DIN: 00462656



**Notes:**

- 1) The above financial results are prepared in accordance with the Indian Accounting Standards ("Ind AS"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under section 133 of the Act read with Rules, 2015 and relevant amendment thereafter.
- 2) These results have been reviewed and recommended for adoption by the Audit Committee and approved by the Board of Directors at their respective meeting held on February 06, 2024.
- 3) As required under Regulation 33 of the SEBI (LODR) Regulations, 2015, the Statutory Auditors have issued Limited Review Reports on the aforesaid unaudited financial results for the quarter and nine months ended 31st December, 2023, which were also approved by the Audit Committee and Board at their meeting held on Tuesday, 06th February, 2024.
- 4) The consolidated accounts have been prepared as per Accounting Standard (AS) 21 on consolidated financial statements.
- 5) As previously disclosed in the financial report for the half year ending September 30, 2023, a fire occurred at the company's manufacturing plant located in Village Nag Kalan, Majitha Road, Amritsar on October 5, 2023. The company has notified the insurance company about the loss of assets, and while an interim claim has been received, the final assessment of the physical damage caused by the fire is still ongoing. Consequently, no impact from the fire-related losses has been accounted for in the financial statements for the quarter ended December 31, 2023, as well as the nine months ended December 31, 2023.


6) List of Subsidiary as on 31st December, 2023 is as under :

Name of Entity	Relationship	Country of Incorporation	% of ownership
Kwality Pharmaceuticals Africa, Limitada	Subsidiary	Africa	51%


7) Figures of Previous Year/Period have been regrouped /recast wherever necessary, in order to make them comparable.

8) The company is primarily engaged in the business of Pharmaceuticals which is single reportable segment for the quarter and nine months ended 31st December, 2023 in accordance with Ind AS 108 - "Operating Segment" and hence no separate segment reporting is given.

For Kwality Pharmaceuticals Limited



(RAMESH ARORA)  
MANAGING DIRECTOR  
DIN: 00462656



Place: Amritsar  
Date: 06-02-2024